Evidence map›Paper›PMID 34115198›Full record

ArticleActa neuropathologica2021

The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.

Tim E Moors, Christina A Maat, Daniel Niedieker, Daniel Mona, Dennis Petersen, Evelien Timmermans-Huisman, Jeroen Kole, Samir F El-Mashtoly, Liz Spycher, Wagner Zago and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 150 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Parkinson disease is a fatty acidopathy.Nature reviews. Neurology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 4 countries.

Tim E MoorsDepartment of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Christina A MaatDepartment of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Daniel NiediekerDepartment of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
Daniel MonaRoche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
Dennis PetersenDepartment of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
Evelien Timmermans-HuismanDepartment of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Jeroen KoleDepartment of Physiology, Amsterdam UMC, Location VU University Medical Center, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Samir F El-MashtolyDepartment of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
Liz SpycherRoche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
Wagner ZagoProthena Biosciences Inc, South San Francisco, CA, 94080, USA.
Robin BarbourProthena Biosciences Inc, South San Francisco, CA, 94080, USA.
Olaf MundiglRoche Pharma Research and Early Development, Therapeutic Modalities; Large Molecule Research, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
Klaus KaluzaRoche Pharma Research and Early Development, Therapeutic Modalities; Large Molecule Research, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
Sylwia HuberRoche Pharma Research and Early Development; Therapeutic Modalities; Small Molecule Research, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
Melanie N HugRoche Pharma Research and Early Development; Therapeutic Modalities; Small Molecule Research, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
Thomas KremerRoche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.
Mirko RitterRoche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany.
Sebastian DziadekRoche Pharma Research and Early Development; Oncology Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, Basel, Switzerland.
Jeroen J G GeurtsDepartment of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Klaus GerwertDepartment of Biophysics, Ruhr-University Bochum, Universitätsstrasse 150, 44801, Bochum, Germany.
Markus BritschgiRoche Pharma Research and Early Development; Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070, Basel, Switzerland. markus.britschgi@roche.com.
Wilma D J van de BergDepartment of Anatomy and Neurosciences, Clinical Neuroanatomy and Biobanking, Amsterdam Neuroscience, Amsterdam UMC, Location VU University Medical Center, O2 building, room 13 E11, De Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands. wdj.vandeberg@amsterdamumc.nl.ORCID 0000-0002-6175-5357
Roche (Switzerland) · CHAmsterdam Neuroscience · NLRuhr University Bochum · DEProthena (United States) · USAmsterdam UMC Location Vrije Universiteit Amsterdam · NLBrigham and Women's Hospital · USRoche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various post-translationally modified (PTM) proteoforms of alpha-synuclein (aSyn)-including C-terminally truncated (CTT) and Serine 129 phosphorylated (Ser129-p) aSyn-accumulate in Lewy bodies (LBs) in different regions of the Parkinson's disease (PD) brain. Insight into the distribution of these proteoforms within LBs and subcellular compartments may aid in understanding the orchestration of Lewy pathology in PD. We applied epitope-specific antibodies against CTT and Ser129-p aSyn proteoforms and different aSyn domains in immunohistochemical multiple labelings on post-mortem brain tissue from PD patients and non-neurological, aged controls, which were scanned using high-resolution 3D multicolor confocal and stimulated emission depletion (STED) microscopy. Our multiple labeling setup highlighted a consistent onion skin-type 3D architecture in mature nigral LBs in which an intricate and structured-appearing framework of Ser129-p aSyn and cytoskeletal elements encapsulates a core enriched in CTT aSyn species. By label-free CARS microscopy we found that enrichments of proteins and lipids were mainly localized to the central portion of nigral aSyn-immunopositive (aSyn+) inclusions. Outside LBs, we observed that 122CTT aSyn+ punctae localized at mitochondrial membranes in the cytoplasm of neurons in PD and control brains, suggesting a physiological role for 122CTT aSyn outside of LBs. In contrast, very limited to no Ser129-p aSyn immunoreactivity was observed in brains of non-neurological controls, while the alignment of Ser129-p aSyn in a neuronal cytoplasmic network was characteristic for brains with (incidental) LB disease. Interestingly, Ser129-p aSyn+ network profiles were not only observed in neurons containing LBs but also in neurons without LBs particularly in donors at early disease stage, pointing towards a possible subcellular pathological phenotype preceding LB formation. Together, our high-resolution and 3D multicolor microscopy observations in the post-mortem human brain provide insights into potential mechanisms underlying a regulated LB morphogenesis.

Indexed as

Brain ChemistryAgedalpha-SynucleinBiological Specimen BanksCytoplasmCytoskeletonHumansInclusion BodiesLewy BodiesMaleMicroscopy, ConfocalMiddle AgedNeuronsParkinson DiseaseProtein Processing, Post-TranslationalSubcellular Fractionsalpha-SynucleinSNCA protein, humanAlpha-synucleinLewy bodiesParkinson's diseasePost-mortem human brainPost-translational modificationsSuper-resolution microscopy

Identifiers

PMID34115198
PMCPMC8357756
OpenAlexW3169544636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.